Boehringer Ingelheim Pharmaceuticals, Inc.
and **Lilly USA, LLC** cordially invite you
to a presentation

Jardiance® (empagliflozin) tablets 10 mg/25 mg

Jardiance (empagliflozin) tablets 10mg/25mg

A Therapy that, Along with Diet and Exercise, Improves Glycemic Control in Adult Patients with Type 2 Diabetes Mellitus

Featured Guest Speaker

Philip Rasulo, MD

Director

Date
Tuesday, February 03, 2015
Time
6:30 PM ET

Location
Seasons 52
170 University Town Center Drive
Sarasota, FL 34211

RSVP by Wednesday, January 28, 2015 to Teri Folmer at (941) 720-9070
TERI.FOLMER@BOEHRINGER-INGELHEIM.COM

This program is open to healthcare practitioners (HCPs) for whom the information presented is relevant to their practice. Spouses or guests cannot be accommodated.

By registering for this event I agree to allow Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), Lilly USA, LLC, and third parties associated with the execution of this program to contact me, by phone, fax, e-mail, or in person.

BIPI and Lilly USA, LLC have adopted the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals that went into effect on July 1, 2002. Pursuant to the Code, inclusion of health care professionals' spouses or guests is not permitted. We appreciate your understanding and support of our commitment to following the highest ethical standards as related to interactions with healthcare professionals. To comply with federal regulations, attendance at the entire session is required and early departures are not permitted.

INDICATION AND IMPORTANT LIMITATIONS OF USE

JARDIANCE is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JARDIANCE is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

JARDIANCE should not be used in patients with a history of serious hypersensitivity to JARDIANCE or in patients with severe renal impairment, end-stage renal disease, or dialysis.

Please see additional Important Safety Information on the next page and accompanying full Prescribing Information, including Patient Information.

Boehringer Ingelheim

Lilly

IMPORTANT SAFETY INFORMATION (CONTINUED)

WARNINGS AND PRECAUTIONS

Hypotension
JARDIANCE causes intravascular volume contraction. Symptomatic hypotension may occur after initiating JARDIANCE particularly in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics. Before initiating JARDIANCE, assess for volume contraction and correct volume status if indicated. Monitor for signs and symptoms of hypotension after initiating therapy.

Impairment in Renal Function
JARDIANCE increases serum creatinine and decreases eGFR. Renal function should be evaluated prior to initiating JARDIANCE and periodically thereafter. More frequent monitoring is recommended with eGFR below 60 mL/min/1.73 m^2. The risk of impaired renal function with JARDIANCE is increased in elderly patients and patients with moderate renal impairment. JARDIANCE should be discontinued in patients with a persistent eGFR less than 45 mL/min/1.73 m^2.

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
Insulin and insulin secretagogues are known to cause hypoglycemia. The use of JARDIANCE with these agents can increase the risk of hypoglycemia. A lower dose of insulin or the insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with JARDIANCE.

Genital Mycotic Infections
JARDIANCE increases the risk for genital mycotic infections. Patients with a history of chronic or recurrent genital mycotic infections were more likely to develop these infections. Monitor and treat as appropriate.

Urinary Tract Infections
JARDIANCE increases the risk for urinary tract infections. Monitor and treat as appropriate.

Increased Low-Density Lipoprotein Cholesterol (LDL-C)
Increases in LDL-C can occur with JARDIANCE. Monitor and treat as appropriate.

Macrovascular Outcomes
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JARDIANCE or any other antidiabetic drug.

ADVERSE REACTIONS

The most common adverse reactions (>5%) associated with placebo and JARDIANCE 10 mg and 25 mg were urinary tract infections (7.6%, 9.3%, 7.6%, respectively) and female genital mycotic infections (1.5%, 5.4%, 6.4%, respectively).

When JARDIANCE was administered with insulin or sulfonylurea, the incidence of hypoglycemic events was increased.

DRUG INTERACTIONS

Coadministration of JARDIANCE with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion.

USE IN SPECIAL POPULATIONS

Pregnancy
There are no adequate and well-controlled studies of JARDIANCE in pregnant women. JARDIANCE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers
It is not known if JARDIANCE is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from JARDIANCE, discontinue nursing or discontinue JARDIANCE.

Geriatric Use
JARDIANCE is expected to have diminished efficacy in elderly patients with renal impairment. The incidence of volume depletion-related adverse reactions and urinary tract infections increased in patients ≥ 75 years treated with JARDIANCE.

JARPROFISI 8.2.14

Please see accompanying full Prescribing Information, including Patient Information.

Jardiance®
(empagliflozin) tablets
10 mg/25 mg

Boehringer Ingelheim

Lilly